Biomedical Engineering Reference
In-Depth Information
650
600
550
500
450
400
350
10
9
8
7
6
5
300
0
2
4
STX concentration (ng/mL)
6
8
10
0
2
4
6
8
10
A
B
STX concentration (ng/mL)
64
1.15
62
1.1
60
1.05
58
1
56
54 2.6
0.95
2.7
2.8
2.9
3
3.1
3.2
0
2
4
6
8
10
C
D
STX concentration (ng/mL)
D f2 / D f1
64
3.2
3.1
62
3
60
2.9
58
2.8
56
2.7
2.6
54
0
2
4
6
8
10
0
2
4
6
8
10
E
F
STX concentration (ng/mL)
STX concentration (ng/mL)
Figure 14.11
(a) Decrease in the binding rate coefficient, k 1 , with an increase in the STX concentration (in
ng/mL) in solution. (b) Decrease in the binding rate coefficient, k 2 , with an increase in the STX
concentration (in ng/mL) in solution. (c) Increase in the fractal dimension, D f1 , with an increase in
the STX concentration (in ng/mL) in solution. (d) Increase in the binding rate coefficient ratio,
k 2 /k 1 , with an increase in the ratio of the fractal dimensions, D f2 /D f1 . (e) Decrease in the ratio of
the fractal dimension, D f2 /D f1 , with an increase in the STX concentration (in ng/mL) in solution.
(f) Decrease in the ratio of the binding rate coefficients, k 2 /k 1 , with an increase in the STX
concentration (in ng/mL) in solution.
Search WWH ::




Custom Search